I think the issue is a bit more than the DEA not wanting to move, and it's also related to how many studies showing positive effects of psychedelics have severe methodological or other important issues. This podcast summarizes some of those issues very nicely in case anyone's interested: https://www.thestudiesshowpod.com/p/episode-4-psychedelics

[–] IDontHavePantsOn@lemm.ee 3 points 2 years ago

I'll listen to the podcast because I'm sure there's info in it that will be new to me, but I do know drug scheduling creates a purgatory that makes substances difficult to research. When the scheduling means that it can't be produced in amounts to create meaningful clinical studies, the "drugs with no currently accepted medical use" definition is difficult to get out of.

To add on to that, if John Hopkins research labs, the same one that came up with CPR, water purification, and genetic engineering, thinks psilocybin has medical use and merit, I believe them.